Vitamin K antagonist

Overview of Vitamin K antagonists

Overview

Vitamin K antagonists (VKAs) are a class of anticoagulant medications that work by inhibiting the action of vitamin K, which is essential for the synthesis of certain clotting factors. These medications are primarily used to prevent and treat thromboembolic disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent stroke in patients with atrial fibrillation.

Mechanism of Action

VKAs exert their anticoagulant effect by inhibiting the enzyme vitamin K epoxide reductase (VKOR). This enzyme is responsible for the conversion of vitamin K epoxide back to its active form, vitamin K hydroquinone. Active vitamin K is a cofactor for the gamma-carboxylation of glutamic acid residues on the N-terminal regions of vitamin K-dependent proteins, including clotting factors II, VII, IX, and X, as well as proteins C and S. By inhibiting VKOR, VKAs reduce the levels of these clotting factors, thereby prolonging the time it takes for blood to clot.

Common Vitamin K Antagonists

The most commonly used VKA is warfarin, which has been in clinical use for many decades. Other VKAs include acenocoumarol and phenprocoumon, which are used in certain countries. Warfarin is the most widely studied and used VKA globally.

Clinical Use

VKAs are used in various clinical settings:

• Prevention of Stroke in Atrial Fibrillation: Patients with non-valvular atrial fibrillation are at increased risk of stroke due to the formation of blood clots in the atria. VKAs reduce this risk by preventing clot formation.
• Treatment and Prevention of Venous Thromboembolism: VKAs are used to treat acute DVT and PE and to prevent their recurrence.
• Prosthetic Heart Valves: Patients with mechanical heart valves require anticoagulation to prevent thromboembolism, and VKAs are commonly used for this purpose.

Monitoring and Management

The anticoagulant effect of VKAs is monitored using the International Normalized Ratio (INR), which standardizes the prothrombin time (PT) test. The target INR range varies depending on the indication but is typically between 2.0 and 3.0 for most conditions. Regular monitoring is essential to ensure therapeutic efficacy and to minimize the risk of bleeding complications.

Dietary Considerations

Patients on VKAs need to maintain a consistent intake of vitamin K, as fluctuations can affect INR levels. Foods high in vitamin K, such as leafy green vegetables, should be consumed in consistent amounts.

Adverse Effects

The primary adverse effect of VKAs is bleeding, which can range from minor bruising to severe hemorrhage. Other side effects include skin necrosis and, rarely, "purple toe syndrome." Patients should be educated about the signs of bleeding and the importance of regular INR monitoring.

Reversal of Anticoagulation

In cases of excessive anticoagulation or bleeding, VKAs can be reversed by administering vitamin K, either orally or intravenously. In emergencies, prothrombin complex concentrates (PCCs) or fresh frozen plasma (FFP) may be used to rapidly restore clotting factor levels.

Alternatives to VKAs

In recent years, direct oral anticoagulants (DOACs) have become available as alternatives to VKAs. These include dabigatran, rivaroxaban, apixaban, and edoxaban. DOACs have the advantage of fixed dosing and do not require routine INR monitoring, but they are not suitable for all patients.

Related Pages

• Anticoagulant
• Warfarin
• Atrial fibrillation
• Deep vein thrombosis
• Pulmonary embolism

• 

  Rattenvergifwaarschuwing

• 

  Menachinon

• 

  K1 vitamin Mechanism of Action

• 

  Warfarin

• 

  Coumatetralyl

• 

  Phenprocoumon

• 

  Acenocoumarol

• 

  Dicumarol